Nicotine
Substance Abuse and Addictive Disorders
August R. Buchhalter, Reginald V. Fant, Jack E. Henningfield,
Jack E. Henningfield
Pinney Associates, Bethesda, Maryland
The Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorAugust R. Buchhalter, Reginald V. Fant, Jack E. Henningfield,
Jack E. Henningfield
Pinney Associates, Bethesda, Maryland
The Johns Hopkins University School of Medicine, Baltimore, Maryland
Search for more papers by this authorAbstract
Nicotine pharmacology is of interest due to its importance in understanding structure and function of the nervous system, the potential of nicotinic modulating drugs in treating a wide range of disorders, and due to the public health impact of nicotine-driven tobacco use and disease. This chapter includes two sections: one on the pharmacology of nicotine and one on the pharmacological treatment of nicotine dependence and withdrawal. Implications for public health policy also are discussed briefly. Topics presented in the pharmacology of nicotine section include nicotine receptors and their functional adaptations, neurosubstrates of nicotine reinforcement and withdrawal, and nicotine pharmacokinetics. Topics presented in the pharmacological treatment section include nicotine and non-nicotine based pharmacotherapies, their mechanism(s) of action, and pharmacokinetics.
References
- 1 World Health Organization (WHO) (1992). The ICD-10 Classification of Mental Behavioural Disorders. WHO, Geneva.
- 2 American Psychiatric Association (APA) (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th ed., APA, Washington, DC.
- 3 Henningfield, J. E., and Benowitz, N. L. (2004). Pharmacology and nicotine addiction. In Tobacco and Public Health: Science and Policy, P. Boyle, N. Gray, J. E. Henningfield, J. Seffrin, and W. Zatonski, Eds. Oxford University Press, Oxford, pp. 129–147.
- 4 Lewin, L. (1998). Phantastica: A classic survey on the use and abuse of mind-altering plants. Park Street Press, Rochester, VT, p. 256.
- 5 WHO Framework Convention on Tobacco Control (2005). Available at http://www.who.int/tobacco/framework/en, June 14, 2005. Presented in Sydney, Australia.
- 6 Centers for Disease Control and Prevention (2002). Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995–1999. MMWR 51, 300–303.
- 7 Centers for Disease Control and Prevention (CDC) (2005). Targeting Tobacco Use: The Nation's Leading Cause of Death. WHO, Atlanta.
- 8 Markou, A., Koob, G. F., and Henningfield, J. E. (2003). Background paper on the neurobiology of nicotine addiction. Unpublished work.
- 9 Taylor, P. (2001). Agents acting at the neuromuscular junction and autonomic ganglia. In Goodman & Gilman's the Pharmacological Basis of Therapeutics, 10th ed., J. G. Hardman and L. E. Limbird, Eds. McGraw-Hill, New York, pp. 193–213.
- 10 Institute of Medicine (2001). Principles of harm reduction. In Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction, K. Stratton, P. Shetty, R. Wallace, and S. Bondurant, Eds. National Academy Press, Washington, DC, pp. 38–59.
- 11 Watkins, S. S., Koob, G. F., and Markou, A. (2000). Neural mechanisms underlying nicotine addiction: Acute positive reinforcement and withdrawal. Nicotine Tobacco Res. 2, 19–37.
- 12 Pappano, A. J. (1998). Cholinoceptor-activating and cholinesterase-inhibiting drugs. In Basic and Clinical Pharmacology, B. G. Katzung, Ed. Appleton and Lange, Stamford, CT, pp. 90–104.
- 13 Holladay, M. W., Dart, M. J., and Lynch, J. K. (1997). Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 40, 4169–4194.
- 14 Wonnacott, S. (1997). Presynaptic nicotinic ACh receptors. Trends Neurosci. 20, 92–98.
- 15 Sargent, P. B. (1993). The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16, 403–443.
- 16 George, T. P., and O'Malley, S. S. (2004). Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci. 25, 42–48.
- 17 Picciotto, M. R., Caldarone, B. J., King, S. L., and Zachariou, V. (2000). Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22, 451–465.
- 18 Leonard, S., and Bertrand, D. (2001). Neuronal nicotine receptors: From structure to function. Nicotine Tobacco Res. 3, 203–223.
- 19 Picciotto, M. R., Zoli, M., Rimondini, R., Lena, C., Marubio, L. M., Pich, E. M., et al. (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173–177.
- 20 Elgoyhen, A. B., Vetter, D. E., Katz, E., Rothlin, C. V., Heinemann, S. F., and Boulter, J. (2001). Alpha10: A determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells. Proc. Natl. Acad. Sci. USA 98, 3501–3506.
- 21 Picciotto, M. R., Zoli, M., Lena, C., Bessis, A., Lallemand, Y., Le Novere, N., et al. (1995). Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374, 65–67.
- 22 Centers for Disease Control and Prevention (CDC) (1988). Nicotine Addiction: A Report of the Surgeon General. The Health Consequences of Smoking. CDC, Atlanta, GA, pp. 241–375.
- 23 Goldberg, S. R., and Spealman, R. D. (1982). Maintenance and suppression of behavior by intravenous nicotine injections in squirrel monkeys. Fed. Proc. 41, 216–220.
- 24 Henningfield, J. E., and Goldberg, S. R. (1983). Control of behavior by intravenous nicotine injections in human subjects. Pharmacol. Biochem. Behav. 19, 1021–1026.
- 25 Pomerleau, C. S., and Pomerleau, O. F. (1992). Euphoriant effects of nicotine in smokers. Psychopharmacology (Berl.) 108, 460–465.
- 26 Benowitz, N. L. (1996). Pharmacology of nicotine: Addiction and therapeutics. Annu. Rev. Pharmacol. Toxicol. 36, 597–613.
- 27 Lanza, S. T., Donny, E. C., Collins, L. M., and Balster, R. L. (2004). Analyzing the acquisition of drug self-administration using growth curve models. Drug Alcohol Depend. 75, 11–21.
- 28 Donny, E. C., Lanza, S. T., Balster, R. L., Collins, L. M., Caggiula, A., and Rowell, P. P. (2004). Using growth models to relate acquisition of nicotine self-administration to break point and nicotinic receptor binding. Drug Alcohol Depend. 75, 23–35.
- 29 Eissenberg, T., and Balster, R. L. (2000). Initial tobacco use episodes in children and adolescents: Current knowledge, future directions. Drug Alcohol Depend. 59, (Suppl. 1), S41–S60.
- 30 Picciotto, M. R., and Corrigall, W. A. (2002). Neuronal systems underlying behaviors related to nicotine addiction: Neural circuits and molecular genetics. J. Neurosci. 22, 3338–3341.
- 31 Nisell, M., Nomikos, G. G., and Svensson, T. H. (1995). Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol. Toxicol. 76, 157–162.
- 32 Grenhoff, J., Aston-Jones, G., and Svensson, T. H. (1986). Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol. Scand. 128, 351–358.
- 33 Damsma, G., Day, J., and Fibiger, H. C. (1989). Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 168, 363–368.
- 34 Mifsud, J. C., Hernandez, L., and Hoebel, B. G. (1989). Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Res. 478, 365–367.
- 35 Pontieri, F. E., Tanda, G., Orzi, F., and Di Chiara, G. (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382, 255–257.
- 36 Nisell, M., Marcus, M., Nomikos, G. G., and Svensson, T. H. (1997). Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens. J. Neural Transm. 104, 1–10.
- 37 Nisell, M., Nomikos, G. G., and Svensson, T. H. (1994). Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol. Toxicol. 75, 348–352.
- 38 Nisell, M., Nomikos, G. G., and Svensson, T. H. (1994). Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16, 36–44.
- 39 Corrigall, W. A., Coen, K. M., and Adamson, K. L. (1994). Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 653, 278–284.
- 40 Corrigall, W. A., Franklin, K. B., Coen, K. M., and Clarke, P. B. (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl.) 107, 285–289.
- 41 Corrigall, W. A., and Coen, K. M. (1991). Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl.) 104, 171–176.
- 42 Levin, E. D. (1997). Chronic haloperidol administration does not block acute nicotine-induced improvements in radial-arm maze performance in the rat. Pharmacol. Biochem. Behav. 58, 899–902.
- 43 Vidal, C., and Changeux, J. P. (1993). Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro. Neuroscience 56, 23–32.
- 44 Radcliffe, K. A., and Dani, J. A. (1998). Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J. Neurosci. 18, 7075–7083.
- 45 Mansvelder, H. D., and McGehee, D. S. (2000). Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27, 349–357.
- 46 Schilstrom, B., Svensson, H. M., Svensson, T. H., and Nomikos, G. G. (1998). Nicotine and food induced dopamine release in the nucleus accumbens of the rat: Putative role of alpha7 nicotinic receptors in the ventral tegmental area. Neuroscience 85, 1005–1009.
- 47 Schilstrom, B., Nomikos, G. G., Nisell, M., Hertel, P., and Svensson, T. H. (1998). N-Methyl-d-aspartate receptor antagonism in the ventral tegmental area diminishes the systemic nicotine-induced dopamine release in the nucleus accumbens. Neuroscience 82, 781–789.
- 48 Sharples, C. G., Kaiser, S., Soliakov, L., Marks, M. J., Collins, A. C., Washburn, M., et al. (2000). UB-165: A novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J. Neurosci. 20, 2783–2791.
- 49 Markou, A., and Paterson, N. E. (2001). The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tobacco Res. 3, 361–373.
- 50 Cheeta, S., Tucci, S., and File, S. E. (2001). Antagonism of the anxiolytic effect of nicotine in the dorsal raphe nucleus by dihydro-beta-erythroidine. Pharmacol. Biochem. Behav. 70, 491–496.
- 51 Grottick, A. J., Trube, G., Corrigall, W. A., Huwyler, J., Malherbe, P., and Wyler, R., et al. (2000). Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J. Pharmacol. Exp. Ther. 294, 1112–1119.
- 52 Paterson, N. E., Semenova, S., Gasparini, F., and Markou, A. (2003). The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl.) 167, 257–264.
- 53 Fallon, J. H., and Moore, R. Y. (1978). Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol. 180, 545–580.
- 54 Walaas, I., and Fonnum, F. (1979). The distribution and origin of glutamate decarboxylase and choline acetyltransferase in ventral pallidum and other basal forebrain regions. Brain Res. 177, 325–336.
- 55 Sugita, S., Johnson, S. W., and North, R. A. (1992). Synaptic inputs to GABAA and GABAB receptors originate from discrete afferent neurons. Neurosci. Lett. 134, 207–211.
- 56 Klitenick, M. A., DeWitte, P., and Kalivas, P. W. (1992). Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: An in vivo microdialysis study. J. Neurosci. 12, 2623–2632.
- 57 Yim, C. Y., and Mogenson, G. J. (1980). Electrophysiological studies of neurons in the ventral tegmental area of Tsai. Brain Res. 181, 301–313.
- 58 Kalivas, P. W., Churchill, L., and Klitenick, M. A. (1993). GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area. Neuroscience 57, 1047–1060.
- 59 Markou, A., Paterson, N. E., and Semenova, S. (2004). Role of gamma-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: Potential pharmacotherapies for smoking cessation. Ann. NY Acad. Sci. 1025, 491–503.
- 60 Dewey, S. L., Brodie, J. D., Gerasimov, M., Horan, B., Gardner, E. L., and Ashby, C. R., Jr. (1993). A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31, 76–86.
- 61 Fattore, L., Cossu, G., Martellotta, M. C., and Fratta, W. (2002). Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol 37, 495–498.
- 62 Paterson, N. E., Froestl, W., and Markou, A. (2004). The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl.) 172, 179–186.
- 63 Paterson, N. E., Froestl, W., and Markou, A. (2005). Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology 30, 119–128.
- 64 Cousins, M. S., Stamat, H. M., and De Wit, H. (2001). Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tobacco Res. 3, 123–129.
- 65 Sarnyai, Z., Shaham, Y., and Heinrichs, S. C. (2001). The role of corticotropin-releasing factor in drug addiction. Pharmacol. Rev. 53, 209–243.
- 66 Cam, G. R., Bassett, J. R., and Cairncross, K. D. (1979). The action of nicotine on the pituitary-adrenal cortical axis. Arch. Int. Pharmacodyn. Ther. 237, 49–66.
- 67 Andersson, K., Fuxe, K., Eneroth, P., Agnati, L. F., and Harfstrand, A. (1987). Effects of acute continuous exposure of the rat to cigarette smoke on amine levels and utilization in discrete hypothalamic catecholamine nerve terminal systems and on neuroendocrine function. Naunyn Schmiedebergs Arch. Pharmacol. 335, 521–528.
- 68 Matta, S. G., Beyer, H. S., McAllen, K. M., and Sharp, B. M. (1987). Nicotine elevates rat plasma ACTH by a central mechanism. J. Pharmacol. Exp. Ther. 243, 217–226.
- 69 Hillhouse, E. W., and Milton, N. G. (1989). Effect of acetylcholine and 5-hydroxytryptamine on the secretion of corticotrophin-releasing factor-41 and arginine vasopressin from the rat hypothalamus in vitro. J. Endocrinol. 122, 713–718.
- 70 Kasckow, J. W., Regmi, A., Sheriff, S., Mulchahey, J., and Geracioti, T. D., Jr. (1999). Regulation of corticotropin-releasing factor messenger RNA by nicotine in an immortalized amygdalar cell line. Life Sci. 65, 2709–2714.
- 71 Okuda, H., Shioda, S., Nakai, Y., Nakayama, H., Okamoto, M., and Nakashima, T. (1993). The presence of corticotropin-releasing factor-like immunoreactive synaptic vesicles in axon terminals with nicotinic acetylcholine receptor-like immunoreactivity in the median eminence of the rat. Neurosci. Lett. 161, 183–186.
- 72 Valentine, J. D., Matta, S. G., and Sharp, B. M. (1996). Nicotine-induced cFos expression in the hypothalamic paraventricular nucleus is dependent on brainstem effects: Correlations with cFos in catecholaminergic and noncatecholaminergic neurons in the nucleus tractus solitarius. Endocrinology 137, 622–630.
- 73 Matta, S. G., Valentine, J. D., and Sharp, B. M. (1997). Nicotinic activation of CRH neurons in extrahypothalamic regions of the rat brain. Endocrine 7, 245–253.
- 74 Stalke, J., Hader, O., Bahr, V., Hensen, J., Scherer, G., and Oelkers, W. (1992). The role of vasopressin in the nicotine-induced stimulation of ACTH and cortisol in men. Clin. Investigator. 70, 218–223.
- 75 Seyler, L. E., Jr., Fertig, J., Pomerleau, O., Hunt, D., and Parker, K. (1984). The effects of smoking on ACTH and cortisol secretion. Life Sci. 34, 57–65.
- 76 Newhouse, P. A., Sunderland, T., Narang, P. K., Mellow, A. M., Fertig, J. B., Lawlor, B. A., et al. (1990). Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with Alzheimer's disease. Psychoneuroendocrinology 15, 471–484.
- 77 Wilkins, J. N., Carlson, H. E., Van Vunakis, H., Hill, M. A., Gritz, E., and Jarvik, M. E. (1982). Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers. Psychopharmacology (Berl.) 78, 305–308.
- 78 Mendelson, J. H., Sholar, M. B., Goletiani, N., Siegel, A. J., and Mello, N. K. (2005). Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology. 30, 1751–1763.
- 79 Koh, H. K. (2002). Accomplishments of the Massachusetts Tobacco Control Program. Tobacco Control 11(Suppl. 2) ii1–ii3.
- 80 Gilbert, D. G., Meliska, C. J., Williams, C. L., and Jensen, R. A. (1992). Subjective correlates of cigarette-smoking-induced elevations of peripheral beta-endorphin and cortisol. Psychopharmacology 106, 275–281.
- 81 Boyadjieva, N. I., and Sarkar, D. K. (1997). The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci. 61, L59–L66.
- 82 Pomerleau, O. F., and Pomerleau, C. S. (1984). Neuroregulators and the reinforcement of smoking: Towards a biobehavioral explanation. Neurosci. Biobehav. Rev. 8, 503–513.
- 83 Houdi, A. A., Pierzchala, K., Marson, L., Palkovits, M., and Van Loon, G. R. (1991). Nicotine-induced alteration in Tyr-Gly Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12, 161–166.
- 84 Pierzchala, K., Houdi, A. A., and Van Loon, G. R. (1987). Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Peptides 8, 1035–1043.
- 85 Tempel, A., and Zukin, R. S. (1987). Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proc. Natl. Acad. Sci. USA 84, 4308–4312.
- 86 Davenport, K. E., Houdi, A. A., and Van Loon, G. R. (1990). Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: Evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113, 40–46.
- 87 Pomerleau, O. F. (1998). Endogenous opioids and smoking: A review of progress and problems. Psychoneuroendocrinology 23, 115–130.
- 88 Gorelick, D. A., Rose, J., and Jarvik, M. E. (1988). Effect of naloxone on cigarette smoking. J. Subst. Abuse., 1, 153–159.
- 89 Karras, A., and Kane, J. M. (1980). Naloxone reduces cigarette smoking. Life Sci. 27, 1541–1545.
- 90 Wewers, M. E., Dhatt, R., and Tejwani, G. A. (1998). Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl.) 140, 185–190.
- 91 Covey, L. S., Glassman, A. H., and Stetner, F. (1999). Naltrexone effects on short-term and long-term smoking cessation. J. Addict. Dis. 18, 31–40.
- 92 Sutherland, G., Stapleton, J. A., Russell, M. A., and Feyerabend, C. (1995). Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology (Berl.) 120, 418–425.
- 93 Nemeth-Coslett, R., and Griffiths, R. R. (1986). Naloxone does not affect cigarette smoking. Psychopharmacology (Berl.) 89, 261–264.
- 94 George, T. P., and O'Malley, S. S. (2004). Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci. 25, 42–48.
- 95 Mansvelder, H. D., Keath, J. R., and McGehee, D. S. (2002). Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33, 905–919.
- 96 Flores, C. M., Davila-Garcia, M. I., Ulrich, Y. M., and Kellar, K. J. (1997). Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration. J. Neurochem. 69, 2216–2219.
- 97 Sanderson, E. M., Drasdo, A. L., McCrea, K., and Wonnacott, S. (1993). Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region-specific. Brain Res. 617, 349–352.
- 98 Benwell, M. E., Balfour, D. J., and Anderson, J. M. (1988). Evidence that tobacco smoking increases the density of (−)-[3 H]nicotine binding sites in human brain. J. Neurochem. 50, 1243–1247.
- 99 Breese, C. R., Marks, M. J., Logel, J., Adams, C. E., Sullivan, B., Collins, A. C., et al. (1997). Effect of smoking history on [3 H]nicotine binding in human postmortem brain. J. Pharmacol. Exp. Ther. 282, 7–13.
- 100 Perry, D. C., Davila-Garcia, M. I., Stockmeier, C. A., and Kellar, K. J. (1999). Increased nicotinic receptors in brains from smokers: Membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther. 289, 1545–1552.
- 101 Benhammou, K., Lee, M., Strook, M., Sullivan, B., Logel, J., Raschen, K., et al. (2000). [(3)H]Nicotine binding in peripheral blood cells of smokers is correlated with the number of cigarettes smoked per day. Neuropharmacology 39, 2818–2829.
- 102 Quick, M. W., and Lester, R. A. (2002). Desensitization of neuronal nicotinic receptors. J. Neurobiol. 53, 457–478.
- 103 Buisson, B., and Bertrand, D. (2002). Nicotine addiction: The possible role of functional upregulation. Trends Pharmacol. Sci. 23, 130–136.
- 104 Buisson, B., and Bertrand, D. (2001). Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J. Neurosci. 21, 1819–1829.
- 105 Marks, M. J., Pauly, J. R., Gross, S. D., Deneris, E. S., Hermans-Borgmeyer, I., Heinemann, S. F., et al. (1992). Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J. Neurosci. 12, 2765–2784.
- 106 Rowell, P. P., and Wonnacott, S. (1990). Evidence for functional activity of up-regulated nicotine binding sites in rat striatal synaptosomes. J. Neurochem. 55, 2105–2110.
- 107 Marks, M. J., Grady, S. R., and Collins, A. C. (1993). Downregulation of nicotinic receptor function after chronic nicotine infusion. J. Pharmacol. Exp. Ther. 266, 1268–1276.
- 108 Gentry, C. L., Wilkins, L. H., and Lukas, R. J. (2003). Effects of prolonged nicotinic ligand exposure on function of heterologously expressed, human alpha4beta2- and alpha4beta4-nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 304, 206–216.
- 109 Epping-Jordan, M. P., Watkins, S. S., Koob, G. F., and Markou, A. (1998). Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393, 76–79.
- 110 Schwartz, R. D., and Kellar, K. J. (1985). In vivo regulation of [3 H] acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J. Neurochem. 45, 427–433.
- 111 Hulihan-Giblin, B. A., Lumpkin, M. D., and Kellar, K. J. (1990). Effects of chronic administration of nicotine on prolactin release in the rat: Inactivation of prolactin response by repeated injections of nicotine. J. Pharmacol. Exp. Ther. 252, 21–25.
- 112 el Bizri, H., and Clarke, P. B. (1994). Regulation of nicotinic receptors in rat brain following quasi-irreversible nicotinic blockade by chlorisondamine and chronic treatment with nicotine. Br. J. Pharmacol. 113, 917–925.
- 113
Kellar, K. J.,
Davila-Garcia, M. I., and
Xiao, Y.
(1999).
Pharmacology of neuronal nicotinic acetylcholine recceptors: Effects of acute and chronic nicotine.
Nicotine Tobacco Res.
1(Suppl. 2),
S117–S120.
10.1080/14622299050011921 Google Scholar
- 114 Royal College of Physicians (2000). Nicotine Addiction In Britain: A Report of the Tobacco Advisory Group of the Royal College of Physicians. Royal College of Physicians of London, London.
- 115 Swedberg, M. D. B., Henningfield, J. E., and Goldberg, S. R. (1990). Nicotine dependency: Animal studies. In Nicotine Psychopharmacology: Molecular, Cellular, and Behavioural Aspects, S. Wonnacott, M. A. H. Russell, and I. P. Stolerman, Eds. Oxford University Press, Oxford, pp. 38–76.
- 116 Collins, A. C., and Marks, M. J. (1989). Chronic nicotine exposure and brain nicotinic receptors—influence of genetic factors. Prog. Brain Res. 79, 137–146.
- 117 Balfour, D. J., and Fagerstrom, K. O. (1996). Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol. Ther. 72, 51–81.
- 118 Soria, R., Stapleton, J. M., Gilson, S. F., Sampson-Cone, A., Henningfield, J. E., and London, E. D. (1996). Subjective and cardiovascular effects of intravenous nicotine in smokers and non-smokers. Psychopharmacology (Berl.) 128, 221–226.
- 119 U.S. Department of Health and Human Services (1998). The Health Consequences of Smoking: Nicotine Addiction, a Report of the Surgeon General. U.S. Government Printing Office, Washington, DC.
- 120 Heishman, S. J., and Henningfield, J. E. (2000). Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers. Psychopharmacology 152, 321–333.
- 121 Hughes, J. R., and Hatsukami, D. (1986). Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry 43, 289–294.
- 122 Shiffman, S. M., and Jarvik, M. E. (1976). Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berl.) 50, 35–39.
- 123 Malin, D. H., Lake, J. R., Newlin-Maultsby, P., Roberts, L. K., Lanier, J. G., Carter, V. A., et al. (1992). Rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 43, 779–784.
- 124 Hildebrand, B. E., Nomikos, G. G., Bondjers, C., Nisell, M., and Svensson, T. H. (1997). Behavioral manifestations of the nicotine abstinence syndrome in the rat: Peripheral versus central mechanisms. Psychopharmacology 129, 348–356.
- 125 Isola, R., Vogelsberg, V., Wemlinger, T. A., Neff, N. H., and Hadjiconstantinou, M. (1999). Nicotine abstinence in the mouse. Brain Res. 850, 189–196.
- 126 Carboni, E., Bortone, L., Giua, C., and DiChiara, G. (2000). Dissociation of physical abstinence signs from changes in extracellular dopamine in the nucleus accumbens and in the prefontal cortex of nicotine dependent rats. Drug Alcohol Depend. 58, 93–102.
- 127 Semenova, S., Bespalov, A., and Markou, A. (2003). Decreased prepulse inhibition during nicotine withdrawal in DBA/2J mice is reversed by nicotine self-administration. Eur. J. Pharmacol. 472, 99–110.
- 128 Droungas, A., Ehrman, R. N., Childress, A. R., and O'Brien, C. P. (1995). Effect of smoking cues and cigarette availability on craving and smoking behavior. Addict. Behav. 20, 657–673.
- 129 Buchhalter, A. R., Acosta, M. C., Evans, S. E., Breland, A. B., and Eissenberg, T. (2005). Tobacco abstinence symptom suppression: The role played by the smoking-related stimuli that are delivered by denicotinized cigarettes. Addiction 100, 550–559.
- 130 Hatsukami, D. K., Hughes, J. R., Pickens, R. W., and Svikis, D. (1984). Tobacco withdrawal symptoms: An experimental analysis. Psychopharmacology (Berl.) 84, 231–236.
- 131 Myrsten, A. L., Elgerot, A., and Edgren, B. (1977). Effects of abstinence from tobacco smoking on physiological and psychological arousal levels in habitual smokers. Psychosom. Med. 39, 25–38.
- 132 Pickworth, W. B., Fant, R. V., Butschky, M. F., and Henningfield, J. E. (1996). Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J. Pharmacol. Exp. Ther. 279, 450–456.
- 133 Shiffman, S. M. (1979). The tobacco withdrawal syndrome. NIDA Res. Monogr. 23, 158–184.
- 134 Watkins, S. S., Stinus, L., Koob, G. F., and Markou, A. (2000). Reward and somatic changes during precipitated nicotine withdrawal in rats: Centrally and peripherally mediated effects. J. Pharmacol. Exp. Ther. 292, 1053–1064.
- 135 Cryan, J. F., Bruijnzeel, A. W., Skjei, K. L., and Markou, A. (2003). Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168, 347–358.
- 136 Tloczynski, J., Malinowski, A., and Lamorte, R. (1997). Rediscovering and reapplying contingent informal medication. Psychologia 40, 14–21.
- 137 Carroll, M. E., Lac, S. T., Asencio, M., and Keenan, R. M. (1989). Nicotine dependence in rats. Life Sci. 45, 1381–1388.
- 138 Helton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., and Kallman, M. J. (1997). LY354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 36, 1511–1516.
- 139 Harrison, A. A., Liem, Y. T., and Markou, A. (2001). Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25, 55–71.
- 140 Fung, Y. K., Schmid, M. J., Anderson, T. M., and Yuen-Sum, L. (1996). Effects of nicotine withdrawal on central dopaminergic systems. Pharmacol. Biochem. Behav. 53, 635–640.
- 141 Hildebrand, B. E., Nomikos, G. G., Hertel, P., Schilstrom, B., and Svensson, T. H. (1998). Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res. 779, 214–225.
- 142 Panagis, G., Hildebrand, B. E., Svensson, T. H., and Nomikos, G. G. (2003). Selective c-fos induction and decreased dopamine release in the central nucleus of amygdala in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Synapse 35, 15–25.
- 143 Hildebrand, B. E., Panagis, G., Svensson, T. H., and Nomikos, G. G. (1999). Behavioral and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: Role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology 21, 560–574.
- 144 Rossetti, Z. L., Melis, F., Carboni, S., Diana, M., and Gessa, G. L. (1992). Alcohol withdrawal in rats is associated with a marked fall in extraneuronal dopamine. Alcoholism: Clin. Exper. Res. 16, 529–532.
- 145 Weiss, F., Markou, A., Lorang, M. T., and Koob, G. F. (1992). Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res. 593, 314–318.
- 146 Terry, P., and Katz, J. L. (1997). Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. Psychopharmacology 134, 201–212.
- 147 Nomikos, G. G., Damsma, G., Wenkstern, D., and Fibiger, H. C. (1992). Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 7, 7–14.
- 148 Shoaib, M., Sidhpura, N., and Shafait, S. (2003). Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology 165, 405–412.
- 149 Glick, S. D., Maisonneuve, I. M., and Kitchen, B. A. (2002). Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors. Eur. J. Pharmacol. 448, 185–191.
- 150 Bruijnzeel, A. W., and Markou, A. (2003). Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse 50, 20–28.
- 151 Malin, D. H. (2001). Nicotine dependence: Studies with a laboratory model. Pharmacol. Biochem. Behav. 70, 551–559.
- 152 Harvey, S. C., and Luetje, C. W. (1996). Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. J. Neurosci. 16, 3798–3806.
- 153 Benwell, M. E. M., Balfour, D. J. K., and Anderson, J. M. (1990). Smoking-associated changes in the serotonergic systems of discrete regions of human brain. Psychopharmacology 102, 68–72.
- 154 Kenny, P. J., File, S. E., and Rattray, M. (2001). Nicotine regulates 5-HT(1A) receptor gene expression in the cerebral cortex and dorsal hippocampus. Eur. J. Neurosci. 13, 1267–1271.
- 155
Rasmussen, K.,
Kallman, M. J., and
Helton, D. R.
(1997).
Serotonin-1A antagonists attenuate the effects of nicotine withdrawal on the auditory startle response.
Synapse
27,
145–152.
10.1002/(SICI)1098-2396(199710)27:2<145::AID-SYN5>3.0.CO;2-E CAS PubMed Web of Science® Google Scholar
- 156 Rasmussen, K., and Czachura, J. F. (1997). Nicotine withdrawal leads to increased sensitivity of serotonergic neurons to the 5-HT1A agonist 8-OH-DPAT. Psychopharmacology (Berl.) 133, 343–346.
- 157 Benwell, M. E., and Balfour, D. J. (1982). Effects of chronic nicotine administration on the response and adaptation to stress. Psychopharmacology (Berl.) 76, 160–162.
- 158 Benwell, M. E., and Balfour, D. J. (1979). Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles. Psychopharmacology (Berl.) 63, 7–11.
- 159 Hilleman, D. E., Mohiuddin, S. M., and Delcore, M. G. (1994). Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation. J. Clin. Pharmacol. 34, 222–224.
- 160 Hilleman, D. E., Mohiuddin, S. M., Del Core, M. G., and Sketch, M. H. (1992). Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch. Intern. Med. 152, 350–352.
- 161 West, R., Hajek, P., and McNeill, A. (1991). Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers clinic. Psychopharmacology (Berl.) 104, 91–96.
- 162 Schneider, N. G., Olmstead, R. E., Steinberg, C., Sloan, K., Daims, R. M., and Brown, H. V. (1996). Efficacy of buspirone in smoking cessation: A placebo-controlled trial. Clin. Pharmacol. Ther. 60, 568–575.
- 163 Kirschbaum, C., Wust, S., and Strasburger, C. J. (1992). ‘Normal’ cigarette smoking increases free cortisol in habitual smokers. Life Sci. 50, 435–442.
- 164 Pickworth, W. B., Baumann, M. H., Fant, R. V., Rothman, R. B., and Henningfield, J. E. (1996). Endocrine responses during acute nicotine withdrawal. Pharmacol. Biochem. Behav. 55, 433–437.
- 165 Puddey, I. B., Vandongen, R., Beilin, L. J., and English, D. (1984). Haemodynamic and neuroendocrine consequences of stopping smoking—a controlled study. Clin. Exp. Pharmacol. Physiol. 11, 423–426.
- 166 Frederick, S. L., Reus, V. I., Ginsberg, D., Hall, S. M., Munoz, R. F., and Ellman, G. (1998). Cortisol and response to dexamethasone as predictors of withdrawal distress and abstinence success in smokers. Biol. Psychiatry 43, 525–530.
- 167 Rasmussen, D. D. (1998). Effects of chronic nicotine treatment and withdrawal on hypothalamic proopiomelanocortin gene expression and neuroendocrine regulation. Psychoneuroendocrinology 23, 245–259.
- 168 Andersson, K., Fuxe, K., Eneroth, P., Jansson, A., and Harfstrand, A. (1989). Effects of withdrawal from chronic exposure to cigarette smoke on hypothalamic and preoptic catecholamine nerve terminal systems and on the secretion of pituitary hormones in the male rat. Naunyn Schmiedebergs Arch. Pharmacol. 339, 387–396.
- 169 Malin, D. H., Lake, J. R., Carter, V. A., Cunningham, J. S., and Wilson, O. B. (1993). Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl.) 112, 339–342.
- 170 Zarrindast, M. R., and Farzin, D. (1996). Nicotine attenuates naloxone-induced jumping behaviour in morphine-dependent mice. Eur. J. Pharmacol. 298, 1–6.
- 171 Tome, A. R., Izaguirre, V., Rosario, L. M., Cena, V., and Gonzalez-Garcia, C. (2001). Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromaffin cells. Brain Res. 903, 62–65.
- 172 Benowitz, N. L., Porchet, H., Sheiner, L., and Jacob, P., III. (1988). Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clin. Pharmacol. Ther. 44, 23–28.
- 173 Henningfield, J. E., Stapleton, J. M., Benowitz, N. L., Grayson, R. F., and London, E. D. (1993). Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alchohol Depend. 33, 23–29.
- 174 Benowitz, N. L. (1988). Pharmacologic aspects of cigarette smoking and nicotine addiction. New Engl. J. Med. 319, 1318–1330.
- 175 Tomar, S. L., and Henningfield, J. E. (1997). Review of the evidence that pH is a determinant of nicotine dosage from oral use of smokeless tobacco. Tobacco Control 6, 219–225.
- 176 Fant, R. V., Henningfield, J. E., Nelson, R. A., and Pickworth, W. B. (1999). Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tobacco Control 8, 387–392.
- 177 Henningfield, J. E., Fant, R. V., Radzius, A., and Frost, S. (1999). Nicotine concentration, smoke pH and whole tobacco aqueous pH of some cigar brands and types popular in the United States. Nicotine Tobacco Res. 1, 163–168.
- 178 Feyerabend, C., Ings, R. M. J., and Russell, M. A. H. (1985). Nicotine pharmacokinetics and its application to intake from smoking. Br. J. Clin. Pharmacol. 19, 239–247.
- 179 Benowitz, N. L., Jacob, P., III, Jones, R. T., and Rosenberg, J. (1982). Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J. Pharmacol. Exp. Ther. 221, 368–372.
- 180 Benowitz, N. L., Kuyt, F., Jacob, P., III, Jones, R. T., and Osman, A. L. (1983). Cotinine disposition and effects. Clin. Pharmacol. Ther. 34, 604–611.
- 181 Benowitz, N. L., Herrera, B., and Jacob, P., III (2004). Mentholated cigarette smoking inhibits nicotine metabolism. J. Pharmacol. Exp. Ther. 310, 1208–1215.
- 182 Benowitz, N. L., and Jacob, P., III. (1985). Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J. Pharmacol. Exp. Ther. 234, 153–155.
- 183 Messina, E. S., Tyndale, R. F., and Sellers, E. M. (1997). A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 282, 1608–1614.
- 184 Tyndale, R. F., and Sellers, E. M. (2001). Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab. Disposition 29, 548–552.
- 185 Sellers, E. M., Kaplan, H. L., and Tyndale, R. F. (2000). Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 68, 35–43.
- 186 Henningfield, J. E., and McLellan, A. T. (2005). Medications work for severely addicted smokers: Implications for addiction therapists and primary care physicians. J. Substance Abuse Treatment 28, 1–2.
- 187 Fiore, M. C., Bailey, W. C., Cohen, S. J., Dorfman, S. F., Goldstein, M. G., Gritz, E. R., et al. (2000). Treating Tobacco Use and Dependence. Clinical Practice Guideline. U.S. Department of Health and Human Services, Public Health Service, Rockville, MD.
- 188 U.S. Department of Health and Human Services (DHHS) (2000). Reducing Tobacco Use: A Report of the Surgeon General. DHHS, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
- 189 World Health Organization (WHO) (2004). Policy Recommendations for Smoking Cessation and Treatment of Tobacco Dependence. WHO, Geneva.
- 190 Henningfield, J. E., and Slade, J. (1998). Tobacco dependence medications: Public health and regulatory issues. Food Drug Law J. 53, 75–114.
- 191 Shiffman, S., Mason, K. M., and Henningfield, J. E. (1998). Tobacco dependence treatments: Review and prospectus. Annu. Rev. Public Health 19, 335–358.
- 192 Henningfield, J. E., Fant, R. V., and Gopalan, L. (1998). Non-nicotine medications for smoking cessation. J. Respir. Dis. 19, S33–S42.
- 193 Fiore, M. C. (2000). A clinical practice guideline for treating tobacco use and dependence. JAMA 283, 3244–3254.
- 194 Henningfield, J. E. (1995). Nicotine medications for smoking cessation. New Engl. J. Med. 333, 1196–1203.
- 195
American Psychiatric Association
(1996).
Practice guideline for the treatment of patients with nicotine dependence.
Am. J. Pyschiatry
153,
1–31.
10.1176/ajp.153.10.1 Google Scholar
- 196 U.S. Department of Health and Human Services (DHHS) (1988). The Health Consequences of Smoking. DHHS, Washington, DC, pp. 3–20.
- 197 Henningfield, J. E., Benowitz, N. L., Ahijevych, K., Garrett, B. E., Connolly, G. N., and Wayne, G. F. (2003). Does menthol enhance the addictiveness of cigarettes? An agenda for research. Nicotine Tobacco Res. 5, 9–11.
- 198 Henningfield, J., Pankow, J., and Garrett, B. (2004). Ammonia and other chemical base tobacco additives and cigarette nicotine delivery: Issues and research needs. Nicotine Tobacco Res. 6, 199–205.
- 199 Henningfield, J. E., Benowitz, N. L., Connolly, G. N., Davis, R. M., Gray, N., Myers, M. L., et al. (2004). Reducing tobacco addiction through tobacco product regulation. Tobbaco Control 13, 132–135.
- 200 Henningfield, J. E., Fant, R. V., Gitchell, J., and Shiffman, S. (2000). Tobacco dependence. Global public health potential for new medications development and indications. Ann. NY Acad. Sci. 909, 247–256.
- 201 Goldberg, S. R., Spealman, R. D., Risner, M. E., and Henningfield, J. E. (1983). Control of behavior by intravenous nicotine injections in laboratory animals. Pharmacol. Biochem. Behav. 19, 1011–1020.
- 202 Henningfield, J. E., Miyasato, K., and Jasinski, D. R. (1983). Cigarette smokers self-administer intravenous nicotine. Pharmacol. Biochem. Behav. 19, 887–890.
- 203 West, R. J., Jarvis, M. J., Russell, M. A., Carruthers, M. E., and Feyerabend, C. (1984). Effect of nicotine replacement on the cigarette withdrawal syndrome. Br. J. Addiction 79, 215–219.
- 204 Henningfield, J. E., Goldberg, S. R., Herning, R. I., Jasinski, D. R., Lukas, S. E., Miyasato, K. M., et al., (1986). Human studies of the behavioral pharmacological determinants of nicotine dependence. In Problems of Drug Dependence, (NIDA Research Monograph # 67). L. S. Harris, Ed. National Institute on Drug Abuse, Rockville, MD, pp. 54–65.
- 204a Benowitz, N. L. (1993). Nicotine replacement therapy. What has been accomplished—Can we do better? Drugs 45, 157–170.
- 204b Schneider, N. G., Olmstead, R. E., Franzon, M. A., and Lunell, E. (2001). The nicotine inhaler: Clinical pharmacokinetics and comparison with other nicotine treatments. Clin. Pharmacokinet. 40, 661–684.
- 207 Tiffany, S. T., Cox, L. S., and Elash, C. A. (2000). Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J. Consult. Clin. Psychol. 68, 233–240.
- 208 Waters, A. J., Shiffman, S., Sayette, M. A., Paty, J. A., Gwaltney, C. J., and Balabanis, M. H. (2004). Cue-provoked craving and nicotine replacement therapy in smoking cessation. J. Consult. Clin. Psychol. 72, 1136–1143.
- 209 Sobel, B. F., Sigmon, S. C., and Griffiths, R. R. (2004). Transdermal nicotine maintenance attenuates the subjective and reinforcing effects of intravenous nicotine, but not cocaine or caffeine, in cigarette-smoking stimulant abusers. Neuropsychopharmacology 29, 991–1003.
- 210 Gorsline, J. (1993). Nicotine pharmacokinetics of four nicotine transdermal systems. Health Values 17, 20–24.
- 211 Fant, R. V., Henningfield, J. E., Shiffman, S., Strahs, K. R., and Reitberg, D. P. (2000). A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol. Biochem. Behav. 67, 479–482.
- 212 Benowitz, N. L., Jacob, P., III., and Savanapridi, C. (1987). Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin. Pharmacol. Ther. 41, 467–473.
- 213 Choi, J. H., Dresler, C. M., Norton, M. R., and Strahs, K. R. (2003). Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tobacco Res. 5, 635–644.
- 214 Molander, L., and Lunell, E. (2001). Pharmacokinetic investigation of a nicotine sublingual tablet. Eur. J. Clin. Pharmacol. 56, 813–819.
- 215 Molander, L., Lunell, E., Andersson, S. B., and Kuylenstierna, F. (1996). Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clin. Pharmacol. Ther. 59, 394–400.
- 216 Bergstrom, M., Nordberg, A., Lunell, E., Antoni, G., and Langstrom, B. (1995). Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin. Pharmacol. Ther. 57, 309–317.
- 217 Schneider, N. G., Lunell, E., Olmstead, R. E., and Fagerstrom, K. O. (1996). Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin. Pharmacokinet. 31, 65–80.
- 218 Samaha, A. N., Yau, W. Y., Yang, P., and Robinson, T. E. (2005). Rapid delivery of nicotine promotes behavioral sensitization and alters its neurobiological impact. Biol. Psychiatry 57, 351–360.
- 219 Nemeth-Coslett, R., Henningfield, J. E., O'Keeffe, M. K., and Griffiths, R. R. (1986). Effects of Mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology 88, 420–425.
- 220 Tennant, F. S., Tarver, A. L., and Rawason, R. A., (1984). Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. In Problems of Drug Dependence (NIDA Research Monograph # 49), L. S. Harris, Ed. Health and Human Services National Institute on Drug Abuse, Rockville, MD, pp. 239–246.
- 221 Rose, J. E., Behm, F. M., Westman, E. C., Levin, E. D., Stein, R. M., and Ripka, G. V. (1994). Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56, 86–99.
- 222
Hurt, R. D.
(1999).
New medications for nicotine dependence treatment.
Nicotine Tobacco Res.
1(Suppl. 2),
S175–S179.
10.1080/14622299050012031 Google Scholar
- 223 Picciotto, M. R. (1998). Common aspects of the action of nicotine and other drugs of abuse. Drug Alcohol Depend. 51, 165–172.
- 224 Baldessarini, R. (2001). Drugs and the treatment of psychiatric disorders: Depression and anxiety disorders. In Goodman & Gilman's the Pharmacological Basis of Therapeutics, 10th ed., J. G. Hardman and L. E. Limbird, Eds. McGraw-Hill, New York, pp. 447–483.
- 225 Prochazka, A. V., Weaver, M. J., Keller, R. T., Fryer, G. E., Licari, P. A., and Lofaso, D. (1998). A randomized trial of nortriptyline for smoking cessation. Arch. Intern. Med. 158, 2035–2039.
- 226 Hall, S. M., Reus, V. I., Munoz, R. F., Sees, K. L., Humfleet, G., Hartz, D. T., et al. (1998). Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry 55, 683–689.
- 227 Edwards, N. B., Murphy, J. K., Downs, A. D., Ackerman, B. J., and Rosenthal, T. L. (1989). Doxepin as an adjunct to smoking cessation: A double-blind pilot study. Am. J. Psychiatry 146, 373–376.
- 228 Edwards, N. B., Simmons, R. C., Rosenthal, T. L., Hoon, P. W., and Downs, J. M. (1988). Doxepin in the treatment of nicotine withdrawal. psychomatics 29, 203–206.
- 229 Murphy, J. K., Edwards, N. B., Downs, A. D., Ackerman, B. J., and Rosenthal, T. L. (1990). Effects of doxepin on withdrawal symptoms in smoking cessation. Am. J. Psychiatry 147, 1353–1357.
- 230 Black, S. C. (2004). Cannabinoid receptor antagonists and obesity. Curr. Opin. Investig. Drugs 5, 389–394.
- 231 Cohen, C., Perrault, G., Voltz, C., Steinberg, R., and Soubrie, P. (2002). SR141716, A central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol. 13, 451–463.
- 232 Klesges, R. C., Meyers, A. W., Klesges, L. M., and La Vasque, M. E. (1989). Smoking, body weight, and their effects on smoking behavior: A comprehensive review of the literature. Psychol. Bull. 106, 204–230.
- 233 Pomerleau, O. F. (1998). Endogenous opioids and smoking: A review of progress and problems. Psychoneuroendocrinology 23, 115–130.
- 234 Volpicelli, J. R., Alterman, A. I., Hayashida, M., and O'Brien, C. P. (1992). Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49, 876–880.
- 235 Houtsmuller, E. J., Clemmey, P. A., Sigler, L. A., and Stitzer, M. L. (1996). Effects of naltrexone on smoking and abstinence. In Problems of Drug Dependence 1996: Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, L. S. Harris, Ed. U.S. Department of Health and Human Services, National Institutes of Health, Rockville, MD, p. 68.
- 236 Kessler, D. (2001). A Question of Intent: A Great American Battle with a Deadly Industry. PublicAffairs, New York.
- 237 World Health Organization (WHO) (2001). Advancing Knowledge on Regulating Tobacco Products. WHO, Geneva.
- 238 World Bank (1999). Curbing the Epidemic: Governments and the Economics of Tobacco Control. World Bank, Washington, DC.
- 239 Food and Drug Administration (1996). Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Federal Register 61, 44396–45318.
- 240 Koop, C. E., Richmond, J., and Steinfeld, J. (2004). America's choice: Reducing tobacco addiction and disease. Am. J. Public Health 94, 174–176.
